Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial

Masayuki Takeda, Takeharu Yamanaka, Takashi Seto, Hidetoshi Hayashi, Koichi Azuma, Morihito Okada, Shunichi Sugawara, Haruko Daga, Tomonori Hirashima, Kimio Yonesaka, Yoshiko Urata, Haruyasu Murakami, Haruhiro Saito, Akihito Kubo, Toshiyuki Sawa, Eiji Miyahara, Naoyuki Nogami, Kazuhiko Nakagawa, Yoichi Nakanishi, Isamu Okamoto

Research output: Contribution to journalArticlepeer-review

41 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences